Health Outcomes Research in Medicine
Volume 1, Issue 1 , Pages e29-e37 , July 2010

The Relationship of Opioid Analgesia to Quality of Life in an Adult Sickle Cell Population

References 

  1. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009;62–69
  2. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11:203–217
  3. McQuay H. Opioids in pain management. Lancet. 1999;353:2229–2232
  4. Portenoy RRK, Foley KKM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171–186
  5. American Academy of Pain Medicine; American Pain Society; American Society of Addiction Medicine. Public policy statement on the rights and responsibilities of health care professionals in the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Pain Med. 2004;5:301–302
  6. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother. 2005;19(2):73–78
  7. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain Symptom Manage. 1993;8:279–288
  8. Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with nonmalignant disease: clinical syndrome and treatment. Mt Sinai J Med. 1978;45:233–237
  9. Finlayson RE, Maruta T, Morse RM, Martin MA. Substance dependence and chronic pain: experience with treatment and follow-up results. Pain. 1986;26:175–180
  10. Brozović M, Davies SC, Brownell AI. Acute admissions of patients with sickle cell disease who live in Britain. Br Med J (Clin Res Ed). 1987;294:1206–1208
  11. Jacob E. American Pain Society. Pain management in sickle cell disease. Pain Manag Nurs. 2001;2:121–131
  12. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101
  13. Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood. 2008;111:997–1003
  14. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006;(2):CD003350
  15. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317–1322
  16. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–1651
  17. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008;165:1–95
  18. Ware JS, Snow K, Kosinski M, et al. RAND 36-Item Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, The New England Medical Center; 1993;
  19. Stewart AAL, Hays RRD, Ware JJE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26:724–735
  20. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903–912
  21. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  22. Afenyi-Annan A, Kail M, Combs MR, Orringer EP, Ashley-Koch A, Telen MJ. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion. 2008;48:917–924
  23. Anie KA, Steptoe A. Pain, mood and opioid medication use in sickle cell disease. Hematol J. 2003;4:71–73
  24. Platt O, Brambilla DJ, Rosse W, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644
  25. McClish D, Penberthy L, Bovbjerg V, et al. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005;3:50
  26. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin. 2005;21:1555–1568
  27. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479–491
  28. Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;40:1327–1335
  29. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347:143–147
  30. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4:59
  31. Andrae U. Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea. Biochem Biophys Res Commun. 1984;118:409–415
  32. Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr. 2007;150:623–626

 This work was supported by U54 HL070769 from NHLBI, NIH. LMDC was the Sickle Cell Scholar for the Duke-UNC Comprehensive Sickle Cell Center (HL070769).

 All authors made specific and substantial contributions to the intellectual content of this work. Soheir S. Adam wrote and revised the manuscript, contributed to data entry, interpretation of data, and supporting tables and figures. Marilyn J. Telen contributed to the analysis and interpretation of the data, drafting and revision of the manuscript, and supporting tables and figures. Charles R. Jonassaint contributed to the analysis and interpretation of the data, drafting of the manuscript and supporting tables and figures. Laura M. De Castro oversaw collection of the data and contributed to the interpretation of the data, drafting and revision of the manuscript, and preparation of supporting tables and figures. Jude C. Jonassaint contributed to the conception and design of the study, acquisition of the data, analysis and interpretation of the data, drafting and revision of the manuscript and supporting tables and figures.

 None of the authors have any conflicts of interest to disclose.

PII: S1877-1319(10)00007-8

doi: 10.1016/j.ehrm.2010.04.002

Health Outcomes Research in Medicine
Volume 1, Issue 1 , Pages e29-e37 , July 2010

Article Tools

* Image Usage & Resolution